# An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 4 |
| **Sponsor** | CSL Behring |
| **Enrollment** | 8 participants |

## Key Eligibility Criteria

### Inclusion (2)

• \- Participants must be aged \>=18 years.

• \- Participants must have a confirmed and documented diagnosis of PID, must be IG treatment-naïve and have an IgG level less than or equal to (\<=) 400 milligrams per deciliter(mg/dL) at Screening.

### Exclusion (13)

• \- Participants with hyperprolinemia.

• \- Participants who are receiving the following medications:

• • Systemic corticosteroids (prednisone or equivalent; average daily dose of greater than \[\>\] 15 mg) from 4 weeks before Screening.

• • Any dose of systemic immunosuppressants within 9 months or 5 times the half-life (t½) plus 6 months before Screening, whichever is longer.

• • Any dose of biologic therapies with influence on the immune system (eg, tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors), including investigational agents, within 12 months or 5 times the t½ plus 6 months before Screening, whichever is longer.

... and 8 more (see full listing online)

## Locations (8 total)

Research Solutions of AZ, Litchfield Park, Arizona, United States
Medical Research of Arizona, Scottsdale, Arizona, United States
Immunoe Health Centers, Centennial, Colorado, United States
... and 5 more locations